麓鹏制药董事长兼CEO谭芬来博士。 工作中的谭芬来博士。 在中国创新药发展版图中，创新药老兵谭芬来博士是一个独特的存在。 七年前，在由其主导临床研发的中国首个小分子靶向抗癌药埃克替尼(凯美纳)惠及数十万患者、首个 ALK靶点创新药恩沙替尼蓄势待发之时，他却选择卸下荣光，创立了一家连名字都直抒高远之志的创 新药企业——麓鹏制药。 七年后的今天，他带领团队交出了一份份令人满意的阶段性成绩单：全球首个且唯一共价兼非共价布鲁 顿酪氨酸激酶(BTK)抑制剂洛布替尼，成为中国首个被认定为弥漫大B细胞淋巴瘤(DLBCL)突破性疗法 的BTK抑制剂，并已启动关键性注册Ⅱ期临床研究；针对复发或难治性套细胞淋巴瘤(R/R MCL)的新药 上市申请(NDA)，获国家药品监督管理局药品审评中心(CDE)受理并纳入优先审评程序；启动治疗复发 或难治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(R/R CLL/SLL)的全球三期头对头临床试验，正面挑战国 际制药巨头礼来公司的第三代BTK抑制剂匹妥布替尼，直面全球化竞争。 从杭州西子湖畔到广州黄埔科学城，谭芬来完成的不只是一次地理上的回归，更是一场从"创中国首 个"到"创全球首个"的信念升级。在 ...

Group 1 - The pharmaceutical industry in A-shares is showing a recovery trend, with some companies exceeding performance expectations for 2025 [1][14] - WuXi AppTec expects revenue of approximately 45.456 billion yuan for 2025, a year-on-year increase of about 15.84%, and a net profit of approximately 19.151 billion yuan, a year-on-year increase of about 102.65% [1][15] - WuXi AppTec's performance is driven by stable growth in its main business and the sale of equity in three companies, generating nearly 5.6 billion yuan in revenue [1][15] Group 2 - WoHua Pharmaceutical anticipates a net profit between 80 million and 115 million yuan for 2025, representing a year-on-year increase of 119.76% to 215.90% [2][16] - The growth in WoHua's performance is attributed to the price-volume trade-off trend after the entry of its product into centralized procurement and the extension to outpatient markets [3][17] Group 3 - Kangchen Pharmaceutical expects a net profit between 14.5 million and 17.5 million yuan for 2025, a year-on-year increase of 243% to 315% [4][19] - The company attributes its performance to the absence of goodwill impairment provisions for 2025, following a decline in revenue from a previously acquired business [5][19] Group 4 - Baiaosaitu is projected to achieve a net profit growth of 249.5% in 2025, with expected revenue of 1.31 billion yuan, a year-on-year increase of 37.75% [6][20] - The company began to achieve commercial profitability in 2024, successfully turning around its financial performance [6][20] Group 5 - The Chinese pharmaceutical market is expected to see significant developments in 2026, with a focus on innovative drug research and business development (BD) [7][21] - China has become the second-largest market for innovative drug launches globally, with leading pharmaceutical companies showing R&D intensities close to global averages [7][21] Group 6 - The total value of innovative drug licensing transactions from China is expected to exceed 130 billion USD in 2025, indicating strong recognition of Chinese pipelines by overseas buyers [9][23] - The CXO service industry is recovering, with predictions that the market size will approach 100 billion USD in 2026, driven by increased demand from innovative drug development [9][23] Group 7 - The AI pharmaceutical sector is becoming increasingly active, with significant transactions and the listing of AI companies on stock exchanges [11][25] - The global market for AI solutions in healthcare is projected to grow from 13.7 billion USD in 2022 to 155.3 billion USD by 2030, highlighting the potential for companies in this space [13][27]

Group 1: Overall Industry Outlook - In 2026, the pharmaceutical industry is expected to experience a surge in innovative drugs, a recovery in the CXO sector, transformation in traditional Chinese medicine, contraction of retail pharmacies, restructuring of hospitals, and a wave of mergers and acquisitions, leading to increased industry differentiation and stronger players remaining dominant [1] Group 2: Innovative Drugs - A total of 76 innovative drugs were approved in 2025, marking a 58% increase from the previous year, with over 150 licensing transactions totaling more than $130 billion, indicating robust growth in China's innovative drug sector [3] - Approximately 20 major innovative drugs are anticipated to be approved in China in 2026, covering various therapeutic areas including oncology and rare diseases, with notable examples such as BL-B01D1 for esophageal squamous carcinoma [3][4] Group 3: CXO Sector - The CXO (Contract Research Organization) industry is experiencing a recovery driven by external factors such as U.S. interest rate cuts and increased R&D investments from multinational pharmaceutical companies, alongside domestic demand for CRO services [5][6] - The penetration rate of outsourcing in areas like ADCs and oligonucleotides is expected to rise to 65%, with companies like WuXi AppTec and Kelun Biotech showing strong growth in these segments [6] Group 4: Traditional Chinese Medicine - The Chinese medicine sector is entering an era of refined management, driven by policy upgrades and market innovations, with a focus on quality and cost balance in procurement [7][9] - By the end of 2026, China aims to establish 180 domestic and 30 international standards for traditional Chinese medicine, with the market expected to exceed 1 trillion yuan for the first time in 2024 [9] Group 5: Medical Devices - The medical device industry is shifting from price suppression to innovation-driven growth, with domestic companies rapidly advancing in high-end imaging, surgical robots, and AI medical devices [10] - Chinese medical device companies are increasingly expanding into international markets, with a notable rise in export volumes expected by 2026 [10] Group 6: Retail Pharmacies - The offline pharmacy sector is projected to contract significantly due to the growth of O2O and B2C models, with over 15,975 stores closing by September 2025, reflecting a 73% year-on-year increase in closures [12][13] Group 7: Private Hospitals - Private hospitals are facing severe challenges, with an average of 1.4 closures per day in 2024, and this trend is expected to continue into 2026 due to regulatory pressures and financial difficulties [14][15]

Core Viewpoint - The article highlights the rapid rise of Guangzhou High-tech Zone in the biopharmaceutical industry, showcasing its significant growth and competitive advantages compared to other major biopharmaceutical hubs in China. Summary by Sections Industry Ranking and Growth - Guangzhou High-tech Zone ranked fifth in the national biopharmaceutical industry park competition, showing a remarkable improvement from twelfth place in 2021, climbing seven positions [4][5]. - The number of biopharmaceutical enterprises in Huangpu District has increased from 1,000 to 4,800 since 2017, a growth of 3.8 times, while revenue surged from 65 billion to 240 billion yuan, also a 2.7 times increase [6]. Leading Enterprises and Innovations - Huangpu District is home to 528 high-tech enterprises in the biopharmaceutical sector and 21 listed companies, accounting for 75% of Guangzhou's total [7]. - Notable companies include Kangfang Biotech, which has developed globally innovative dual-specific antibody drugs, and Hengrui Medicine, which has seen its innovative drug sales reach 9.561 billion yuan, making up 60.66% of its total revenue [9]. Competitive Advantages - The article identifies three key advantages for Huangpu's attractiveness to biopharmaceutical giants: top-tier location, superior medical resources, and a robust talent supply [10]. - The Guangdong-Hong Kong-Macao Greater Bay Area's economic scale reached 14.8 trillion yuan in 2024, making it a strategic development zone for pharmaceutical companies [10]. Policy Support and Ecosystem - Huangpu has implemented comprehensive policies to support the biopharmaceutical industry, including significant funding for innovative drug research and development [14]. - The district has established a "white list" system for the import of research materials, significantly reducing customs clearance times for biopharmaceutical companies [14]. Infrastructure and Development Model - Huangpu's industrial layout includes the Biopharmaceutical Island for R&D, the Science City for innovation, and the Knowledge City for production, creating a complete industrial chain [17][18]. - The integration of research, funding, clinical trials, and production within a short distance enhances operational efficiency for biopharmaceutical companies [18]. Future Outlook - Huangpu's development path reflects the broader transformation of China's biopharmaceutical industry, moving from generic drug production to innovative drug development [20].